



(12) Translation of
european patent specification

(11) NO/EP 2612859 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 401/06 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.02.08
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.09.30
(86)	European Application Nr.	11821851.0
(86)	European Filing Date	2011.08.31
(87)	The European Application's Publication Date	2013.07.10
(30)	Priority	2010.08.31, JP, 2010194068
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Kaken Pharmaceutical Co., Ltd., 28-8, Honkomagome 2-chome Bunkyo-ku, Tokyo 113-8650, JP-Japan
(72)	Inventor	MIMURA, Mitsuo, c/o Kaken Pharmaceutical Co. Ltd. Central Research Laboratories 301 Gensuke, Fujieda-shi Shizuoka 426-8646, JP-Japan WATANABE, Masahito, c/o Kaken Pharmaceutical Co. Ltd. Central Research Laboratories 301 Gensuke, Fujieda-shi Shizuoka 426-8646, JP-Japan ISHIYAMA, Nobuo, c/o Kaken Pharmaceutical Co. Ltd. Central Research Laboratories 14 Shinomiyaminamigawara-cho Yamashina-ku, Kyoto-shi Kyoto 607- 8042, JP-Japan YAMADA, Takuya, c/o Kaken Pharmaceutical Co. Ltd. Central Research Laboratories 14 Shinomiyaminamigawara-cho Yamashina-ku, Kyoto-shi Kyoto 607- 8042, JP-Japan
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	METHOD FOR PRODUCING 1-TRIAZOLE-2-BUTANOL DERIVATIVE
(56)	References Cited:	EP-A1- 0 698 606 WO-A1-94/26734 WO-A1-97/11939 OGURA, HIRONOBU ET AL.: 'Synthesis and antifungal activities of (2R,3R)-2-aryl-1-azolyl-3-(substituted amino)-2-butanol derivatives as topical antifungal agents' CHEMICAL & PHARMACEUTICAL BULLETIN vol. 47, no. 10, 1999, pages 1417 - 1425, XP002296880 MIMURA, MITSUO ET AL.: 'Synthesis and evaluation of (piperidinomethylene)bis (phosphonic acid) derivatives as anti- osteoporosis agents' CHEMICAL & PHARMACEUTICAL BULLETIN vol. 41, no. 11, 1993, pages 1971 - 1986

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Fremgangsmåte for å fremstille (2*R*,3*R*)-2-(2,4-difluorfenyl)-3-(4-metylenpiperidin-1-yl)-1-(1*H*-1,2,4-triazol-1-yl)butan-2-ol eller et
5 syreaddisjonssalt derav, som omfatter å omsette (2*R*,3*S*)-2-(2,4-difluorfenyl)-3-metyl-2-[(1*H*-1,2,4-triazol-1-yl)metyl]oksiran med et syreaddisjonssalt av 4-metylenpiperidin i et reaksjonsløsemiddel i nærvær av et hydroksid av et alkalimetall eller et jordalkalimetall valgt fra gruppen bestående av litium og kalsium, eller et hydrat derav.
10
2. Fremgangsmåten ifølge krav 1, hvori hydroksidet av et alkalimetall eller et jordalkalimetallsalt er litiumhydroksid.
3. Fremgangsmåten ifølge krav 1 eller 2, hvori syreaddisjonssaltet av 4-
15 metylenpiperidin er 4-metylenpiperidin-hydrobromid eller 4-metylenpiperidin-hydroiodid.
4. Fremgangsmåten ifølge krav 3, hvori syreaddisjonssaltet av 4-metylenpiperidin er 4-metylenpiperidin-hydrobromid.
20
5. Fremgangsmåten ifølge et hvilket som helst av kravene 1 til 4, hvori reaksjonsløsemiddelet er acetonitril, 1,2-dimetoksyetan, syklopentylmetyleter, isopropanol, 1-butanol eller 4-metyl-2-pentanon.
- 25 6. Fremgangsmåten ifølge krav 5, hvori reaksjonsløsemiddelet er acetonitril eller syklopentylmetyleter.